Laprituximab

Modify Date: 2024-01-11 12:45:24

Use of Laprituximab

Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289[1].

Name	Laprituximab

Description	Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR
In Vivo	在 H292 异种移植瘤模型中，Laprituximab (J2898A) 的最低有效剂量为 3 mg/kg[1]。
References	[1]. Chittenden T D, et al. IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway. Cancer Research, 2013, 73(8_Supplement): 5467-5467.

No Any Chemical & Physical Properties

Get all suppliers and price by the below link: